Sign inJoin waitlistJoin the waitlist

Rajen Mody

Director of Pediatric Precision Oncology · University of Michigan

Credentials: · · ·

History

Pediatric Hematology-Oncology
1991–1992
Pediatrics
1988–1991
Bachelor of Medicine, Bachelor of Surgery
1984–1988

Research

Integrative clinical genomics of metastatic cancer
Nature · 2017 · 697 citations
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth
JAMA · 2015 · First of 35 authors · 344 citations
Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study
Blood · 2008 · First of 9 authors · 306 citations

CK
Carl Koschmann
30 papers
PR
Patricia Robertson
16 papers
Sriram Venneti
16 papers
HG
Hugh Garton
13 papers
VO
Valerie Opipari
12 papers
AF
Andrea Franson
9 papers
GY
Gregory Yanik
9 papers
Barry Shulkin
8 papers
Drew Pratt
8 papers
Karin Muraszko
8 papers
Naomi Winick
8 papers
RH
Raymond Hutchinson
8 papers

Clinical trials

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2018–2024
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2013–2022
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma
Principal investigator · Completed · Phase 1
University of Michigan Rogel Cancer Center
2008–2012
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
Site PI · Recruiting · Phase 1
National Cancer Institute (NCI)
2026–2027